कृपया अन्य खोज का प्रयास करें
Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of COVID-19; inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; and IFN-ß that is in Phase-II clinical trials for the treatment or prevention of chronic obstructive pulmonary disease. The company was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Richard Marsden | 53 | 2004 | CEO, MD & Executive Director |
Simon James Blouet Shaw | 56 | 2003 | Non-Executive Chairman |
Stephen T. Holgate | 73 | 2003 | Co-Founder, Non-Executive Director & Member of Scientific Advisory Board |
Donna Davies | - | - | Co-Founder & Member of Scientific Advisory Board |
Ratko Djukanovic | - | - | Co-Founder & Member of Scientific Advisory Board |
David Bruce Campbell | 78 | 2006 | Non-Executive Director & Member of Scientific Advisory Board |
Phillip David Monk | 54 | 2009 | Chairman of Scientific Advisory Board, Chief Scientific Officer & Executive Director |
Amanda Dawn Radford | 53 | 2022 | Independent Non-Executive Director |
Felicity Jane Gabbay | 71 | 2022 | Member of Scientific Advisory Board & Independent Non-Executive Director |
Joseph Tregonning Colliver | 43 | 2023 | CFO & Executive Director |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है